 |
 Video: What is a Stock Split?
|
|
|
| Equillium is a clinical-stage biotechnology company to develop therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Co.'s pipeline is focused on developing itolizumab (EQ001), EQ101 and EQ102 as potential disease modifying treatments for multiple severe immuno-inflammatory disorders. Co. has active clinical development programs for itolizumab (EQ001) for the treatment of acute graft-versus-host disease and lupus/lupus nephritis. Co. also has a proprietary product discovery platform that it can utilize to design peptides to target and inhibit multiple cytokines that are involved in validated biological and disease pathways. According to our Equillium stock split history records, Equillium has had 0 splits. | |
|
Equillium (EQ) has 0 splits in our Equillium stock split history database.
Looking at the Equillium stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Equillium shares, starting with a $10,000 purchase of EQ, presented on a split-history-adjusted basis factoring in the complete Equillium stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/15/2018 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$14.00 |
|
| End price/share: |
$1.67 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-88.07% |
|
| Average Annual Total Return: |
-31.81% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,192.84 |
|
| Years: |
5.55 |
|
|
|
|
|
